Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Pembrolizumab vs Physician/Patient Choice of High-dose Interferon or Ipilimumab in High-risk Resected Melanoma
2016-005197-35Phase 3Active
- Sponsor
- Cancer Trials Ireland
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in melanoma, sponsored by Cancer Trials Ireland. Started Feb 2017; status: active.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-005197-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005197-35.